Shareholding disclosure

Novartis Forschungsstiftung c/o Novartis International AG

Declared position

5.69%

Threshold

Crossed upwards

Timeline

Published

22.01.2004

Transaction

—

Voting rights breakdown

Voting rights acquired5.69%

Voting rights sold0%

Below threshold0%

Notice details

CategoryGroup of shareholders

ExchangeXSWX

Notification ID

T2395D2367

Beneficial owner

Novartis Forschungsstiftung c/o Novartis International AG

Declared address

Novartis Forschungsstiftung c/o Novartis International AG, Basel

Die Beteiligung an der Cytos Biotechnology AG wurde bis anhin von Novartis Venture Fund gemanagt und wird auch weiterhin von Novartis Venture Fund gemanagt werden.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Novartis Forschungsstiftung c/o Novartis International AG

Kuros Biosciences AG22.01.2004T2395D2367

Disclosure summary

Novartis Forschungsstiftung c/o Novartis International AG disclosed a holding in Kuros Biosciences AG on the acquisition side, published by SIX Exchange Regulation on 22.01.2004, at 5.69% of voting rights. Notice category: Group of shareholders.

Disclosed position

5.69%

Voting rights acquired

Voting rights acquired5.69%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Novartis Forschungsstiftung c/o Novartis International AG disclosed a holding in Kuros Biosciences AG, published on 22.01.2004.

Publication date22.01.2004

Issuing companyKuros Biosciences AG

Beneficial ownerNovartis Forschungsstiftung c/o Novartis International AG

Declared addressNovartis Forschungsstiftung c/o Novartis International AG, Basel

CategoryGroup of shareholders

Voting rights acquired5.69%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDT2395D2367

Conditions

Die Beteiligung an der Cytos Biotechnology AG wurde bis anhin von Novartis Venture Fund gemanagt und wird auch weiterhin von Novartis Venture Fund gemanagt werden.

Source: SIX Exchange Regulation · Publication date: 22.01.2004

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open